Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk.

Anoctamins / genetics Autoantibodies / immunology Cross Reactions / genetics Epstein-Barr Virus Nuclear Antigens / genetics Female HLA-A2 Antigen / immunology HLA-DRB1 Chains / genetics Haplotypes Herpesvirus 4, Human / genetics Humans Immunoglobulin G / immunology Male Models, Immunological Molecular Mimicry Multiple Sclerosis / genetics Risk Factors

ANO2 Anoctamin 2 Epstein-Barr virus molecular mimicry multiple sclerosis

Journal

Proceedings of the National Academy of Sciences of the United States of America

ISSN: 1091-6490

Titre abrégé: Proc Natl Acad Sci U S A

Pays: United States

ID NLM: 7505876

Informations de publication

Date de publication:
20 08 2019

Historique:

pubmed: 4 8 2019

medline: 24 3 2020

entrez: 4 8 2019

Statut: ppublish

Résumé

Multiple sclerosis (MS) is a chronic inflammatory, likely autoimmune disease of the central nervous system with a combination of genetic and environmental risk factors, among which Epstein-Barr virus (EBV) infection is a strong suspect. We have previously identified increased autoantibody levels toward the chloride-channel protein Anoctamin 2 (ANO2) in MS. Here, IgG antibody reactivity toward ANO2 and EBV nuclear antigen 1 (EBNA1) was measured using bead-based multiplex serology in plasma samples from 8,746 MS cases and 7,228 controls. We detected increased anti-ANO2 antibody levels in MS (

Identifiants

DOI: 10.1073/pnas.1902623116 PMID: 31375628 PMC: PMC6708327

pubmed: 31375628

pii: 1902623116

doi: 10.1073/pnas.1902623116

pmc: PMC6708327

doi:

Substances chimiques

ANO2 protein, human 0

Anoctamins 0

Autoantibodies 0

Epstein-Barr Virus Nuclear Antigens 0

HLA-A*02:01 antigen 0

HLA-A2 Antigen 0

HLA-DRB1 Chains 0

HLA-DRB1*15:01 antigen 0

Immunoglobulin G 0

EBV-encoded nuclear antigen 1 O5GA75RST7

Types de publication

Clinical Trial Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

16955-16960

Déclaration de conflit d'intérêts

Conflict of interest statement: Outside this work, T.O. has received unrestricted MS research grants, lecture and/or advisory board honoraria from: Biogen, Novartis, Merck, Sanofi, and Roche. Outside this work, P.K. is working at Roche Diagnostics in unrelated projects.

Références

Tissue Antigens. 2000 Feb;55(2):140-8

pubmed: 10746785

Trends Immunol. 2003 Nov;24(11):584-8

pubmed: 14596882

J Virol. 2005 Jul;79(13):8581-90

pubmed: 15956599

Diabetes. 2005 Dec;54 Suppl 2:S52-61

pubmed: 16306341

J Clin Invest. 1990 Sep;86(3):981-5

pubmed: 1697609

Int Rev Neurobiol. 2007;79:127-47

pubmed: 17531840

Hum Immunol. 2007 Sep;68(9):779-88

pubmed: 17869653

J Exp Med. 2007 Nov 26;204(12):2899-912

pubmed: 17984305

J Exp Med. 2008 Aug 4;205(8):1763-73

pubmed: 18663124

Nat Rev Immunol. 2009 Apr;9(4):246-58

pubmed: 19319143

J Neuroimmunol. 2009 Oct 30;215(1-2):102-7

pubmed: 19733917

Ann Neurol. 2010 Feb;67(2):159-69

pubmed: 20225269

J Neuroimmune Pharmacol. 2010 Sep;5(3):271-7

pubmed: 20369303

J Neuroimmunol. 2010 Aug 25;225(1-2):149-52

pubmed: 20510468

Ann Neurol. 2010 Jun;67(6):824-30

pubmed: 20517945

Mult Scler. 2011 Oct;17(10):1185-93

pubmed: 21685232

Genes Immun. 2012 Jan;13(1):14-20

pubmed: 21776012

J Clin Invest. 2012 Apr;122(4):1180-8

pubmed: 22466660

Brain. 2012 Jun;135(Pt 6):1819-33

pubmed: 22561643

Presse Med. 2012 Dec;41(12 P 2):e626-35

pubmed: 23177474

Diabetes. 2013 Jul;62(7):2618-22

pubmed: 23462545

Mol Cell Proteomics. 2013 Sep;12(9):2657-72

pubmed: 23732997

Bioinformatics. 2014 Mar 15;30(6):884-6

pubmed: 24162465

PLoS Genet. 2013 Nov;9(11):e1003926

pubmed: 24278027

J Intern Med. 2014 Apr;275(4):382-6

pubmed: 24433367

Physiol Rev. 2014 Apr;94(2):419-59

pubmed: 24692353

J Immunol. 2014 Sep 1;193(5):2118-26

pubmed: 25063864

Nature. 2015 Feb 19;518(7539):337-43

pubmed: 25363779

Lancet Neurol. 2015 Mar;14(3):263-73

pubmed: 25662901

J Autoimmun. 2015 Nov;64:13-25

pubmed: 26142251

Nat Genet. 2015 Oct;47(10):1107-1113

pubmed: 26343388

Lancet Neurol. 2016 Feb;15(2):198-209

pubmed: 26724103

Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2188-93

pubmed: 26862169

Curr Opin Neurol. 2016 Jun;29(3):293-8

pubmed: 27035899

Nat Rev Neurol. 2017 Jan;13(1):25-36

pubmed: 27934854

Ann Neurol. 2017 Oct;82(4):554-561

pubmed: 28869671

Cell Immunol. 2019 Jan;335:68-75

pubmed: 30428974

Neurology. 1995 Jun;45(6 Suppl 6):S11-5

pubmed: 7540264

Curr Opin Immunol. 1996 Dec;8(6):831-6

pubmed: 8994863

J Clin Invest. 1998 Sep 15;102(6):1265-73

pubmed: 9739061